The present invention relates to a Siphoviridae bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP) isolated from nature, which has the ability to specifically kill Enterococcus faecium and has the genome represented by SEQ ID NO: 1, a pharmaceutical composition containing the Siphoviridae bacteriophage Ent-FAP-4 as an active ingredient, and a method of preventing or treating a disease caused by Enterococcus faecium using the pharmaceutical composition.